Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.57 |
| ▸ | PPARG | P37231 | 9/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385807 | 1.00 | HRH3 (0.59) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL9123993 | 0.88 | HRH3 (0.57) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL8133025 | 0.84 | HRH3 (0.57) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL8126354 | 0.83 | HRH3 (0.56) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL6505839 | 0.82 | PPARG (0.46) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL8460445 | 0.82 | FFAR1 (0.57) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL8796744 | 0.79 | PPARG (0.55) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL6898288 | 0.79 | PPARG (0.56) | HRH3FFAR1PPARGPPARAMEN1 | |
| SCHEMBL7834886 | 0.78 | MEN1 (0.37) | HRH3FFAR1PPARGMEN1ALDH1A1 | |
| SCHEMBL8128813 | 0.78 | PPARG (0.63) | HRH3FFAR1PPARGPPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20240036046-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | IMAMITSUKAI MEDICAL CORPORATION (JP) | 2024-02-01 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| EP-4252773-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | Imamitsukai Medical Corporation (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887388-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20010016586-A1 | Use of organic compounds | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
| WO-2001052825-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001047514-A1 | USE OF HYPOGLYCEMIC AGENT FOR TREATING IMPAIRED GLUCOSE METABOLISM | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001026639-A2 | PHARMACEUTICAL COMPOSITION OF ATEGLINIDE AND ANOTHER ANTIDIABETICAGENT | NOVARTIS AG (CH) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001021159-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETCAGENT | NOVARTIS AG (CH) | 2001-03-29 | — | — | WO | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | HRH3 2147/4885FFAR1 256/4885PPARG 3245/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | HRH3 1895/4885FFAR1 1045/4885PPARG 3421/4885 |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | HRH3 915/4885FFAR1 654/4885PPARG 3634/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | HRH3 1090/4885FFAR1 144/4885PPARG 2984/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | HRH3 1895/4885FFAR1 1045/4885PPARG 3421/4885 |
| US-20010016586-A1 | Use of organic compounds | APOL1, APOB, SLC5A2 | HRH3 4158/4885FFAR1 1139/4885PPARG 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.